Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: verathon.com
Global Number of Employees (Latest): 400
Year Founded: 1984
Total Amount Raised (CAD mm)†: 20.32
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Verathon Inc. designs, manufactures, and markets medical devices for the health care community in the United States and internationally. It offers BladderScan, a bladder volume measurement instrument that assesses urinary retention and postoperative urinary retention, prevents unnecessary catheterization, reduces rates of catheter-associated urinary tract infection, and manages foley catheter use and incontinence issues. The company also provides GlideScope video laryngoscope that provides a view of the airway enabling intubation for use in anesthesiology, critical care, military, and emergency medicine markets; ImageSense, a medical equipment that analyzes image; CAUTI Zero; and AortaScan AMI 9700, a noninvasive 3D ultrasound solution that provides ultrasonic reflections to measure the diameter of abdominal aorta. In addition, it offers encore, a refurbished portable 3D ultrasound equipment. Verathon Inc. was formerly known as Diagnostic Ultrasound Corporation and changed its name to Verathon Inc. in October 2006. The company was founded in 1984 and is headquartered in Bothell, Washington. It has locations in Vancouver, Canada; London, United Kingdom; Paris, France; Amsterdam, the Netherlands; Dusseldorf, Germany; Shanghai, China; Singapore; Tokyo, Japan; and Sydney, Australia. As of December 3, 2009, Verathon Inc. operates as a subsidiary of Roper Technologies, Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
 150.2
Operating Income
-
Total Assets
 84.4
Gross Profit
 114.6
EBITDA
-
Total Debt
-
Net Income
 18.9
Global Number of Employees (Latest)
 400
Net Debt
-
U.S. Number of Employees 2014
 332
U.S. Number of Employees 2013
-
U.S. Last Year Employee Growth %
-
Private Co. Financial Data  as of Dec-31-2008. * Hover over data point numbers for date and source.

Key Professionals
Name
Title
McMorrow, Gerald 
Founder, Chairman of the Board and Chief Executive Officer
Thompson, Earl R.
President
Davidson, Barbara
Chief Financial Officer and Vice President of Finance
Dunne, Maurice
Vice President of Operations
Mueller, Jane
Vice President of Marketing
Murphy, Brenda 
Vice President of People
Pacey, John A.
Chief Executive Officer of Verathon Medical (Canada) ULC

Key Board Members
Name
Title
McMorrow, Gerald 
Founder, Chairman of the Board and Chief Executive Officer


Primary Industry Classification
Health Care Equipment


Primary Office Location
20001 North Creek Parkway | Bothell, WA | 98011 | United States
Phone: 425 867 1348   Fax: 425 883 2896

Parent Company
Roper Technologies, Inc. (NasdaqGS:ROP)

Prior Investors
DW Healthcare Partners Fund I, L.P., DW Management Services, LLC, Rho Capital Partners, Inc., Rho Ventures VI, L.P.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Heartscape Technologies, Inc.
As of February 22, 2010, Heartscape Technologies, Inc. was acquired by Verathon Inc. Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports. The company was founded in 2005 and is based in Columbia, Maryland.

United States and Canada
Health Care Equipment
-
-
-
Verathon Medical (Australia) Pty Limited
Verathon Medical (Australia) Pty Limited operates as a subsidiary of Verathon Inc.

Asia / Pacific
-
-
-
-
Verathon Medical (Europe) B.V.
Verathon Medical (Europe) B.V. operates as a subsidiary of Verathon Inc.

Europe
Health Care Equipment
6.00
-
-
Verathon Medical (France) S.a.r.l.
Verathon Medical (France) S.a.r.l. operates as a subsidiary of Verathon Inc.

Europe
-
-
-
-
Verathon Medical (Hong Kong) Limited
Verathon Medical (Hong Kong) Limited operates as a subsidiary of Verathon Inc.

Asia / Pacific
-
-
-
-
Verathon Medical (Japan) K.K.
Verathon Medical (Japan) K.K. operates as a subsidiary of Verathon Inc.

Asia / Pacific
-
-
-
-
Verathon Medical (Uk) Ltd
Verathon Medical (Uk) Ltd operates as a distributor of miscellaneous products. The company was formerly known as Diagnostic Ultrasound (Uk) Ltd.  and changed its name to Verathon Medical (Uk) Ltd in October 2006. Verathon Medical (Uk) Ltd was incorporated in 1999 and is based in Birmingham, United Kingdom. Verathon Medical (Uk) Ltd operates as a subsidiary of Verathon Inc.

Europe
Trading Companies and Distributors
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-28-2010
Feb-22-2010
Merger/Acquisition
Buyer
Heartscape Technologies, Inc.
Verathon Inc.
Radius Ventures, LLC,Scottish Equity Partners LLP
-
Nov-06-2009
Dec-03-2009
Merger/Acquisition
Target
Verathon Inc.
Roper Industries, Inc. (nka:Roper Technologies, Inc. (NasdaqGS:ROP))
DW Management Services, LLC,Rho Capital Partners, Inc. Seller Funds:DW Healthcare Partners Fund I, L.P.
-
Jan-5-2006
Jan-5-2006
Merger/Acquisition
Buyer
Saturn Biomedical Systems, Inc. (nka:Verathon Medical (Canada) ULC)
Diagnostic Ultrasound Corporation (nka:Verathon Inc.)

-
Mar-31-2005
Mar-31-2005
Private Placement
Target
Diagnostic Ultrasound Corporation (nka:Verathon Inc.)
DW Management Services, LLC,Rho Capital Partners, Inc. Buyer Funds:DW Healthcare Partners Fund I, L.P.

16.80
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-16-2017
Product-Related Announcements
Verathon Inc. Launches New GlideScope Spectrum Single-Use Video Laryngoscopes
May-06-2016
Client Announcements
Verathon Inc. Wins $28.98 Million Federal Contract
Jan-28-2016
Product-Related Announcements
Verathon Launches New Portable 3D Ultrasound Instrument: BladderScan Prime
Jun-11-2015
Client Announcements
Verathon Inc. Wins $95.37 Million Federal Contract
Nov-30-2012
Product-Related Announcements
Verathon Inc. Issues Voluntary Recall of Certain GlideScope GVL Video Laryngoscope Reusable Blades

M&A Advisors
Harris Williams LLC


Advisors
M&A Advisors
Harris Williams LLC


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 08, 2023 12:19 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
27
GlobalData

Jun 08, 2023 02:49 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
28
GlobalData

Mar 06, 2023 10:59 PM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
28
GlobalData

Dec 08, 2022 12:12 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
28
GlobalData

Sep 12, 2022 03:30 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
28
GlobalData

Jun 13, 2022 03:12 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
28
GlobalData

Mar 10, 2022 01:55 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
28
GlobalData

Dec 10, 2021 01:41 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
28
GlobalData

Sep 09, 2021 03:45 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
20
GlobalData

Jun 09, 2021 10:58 AM
Verathon Inc.
Verathon Inc - Strategic SWOT Analysis Review
Reports
24


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
BladderScan Products, FloPoint Elite Uroflow System, GlideScope AVL Reusable Video Laryngoscope, GlideScope Cobalt Single-Use Video Laryngoscope, GlideScope Direct Intubation Trainer, GlideScope Ranger Single Use Video Laryngoscope, GlideScope Spectrum Single-Use Video Laryngoscopes, Heartscape 3D ECG System

Key Board Members Details
Name
Title
Phone
Fax
Email
McMorrow, Gerald 
Founder, Chairman of the Board and Chief Executive Officer
(425) 922-2884
425 883 2896
GERALD.MCMORROW@VERAVANTI.COM
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
McMorrow, Gerald 
Founder, Chairman of the Board and Chief Executive Officer
(425) 922-2884
425 883 2896
GERALD.MCMORROW@VERAVANTI.COM
Thompson, Earl R.
President
425 867 1348
425 883 2896
-
Davidson, Barbara
Chief Financial Officer and Vice President of Finance
425 867 1348
425 883 2896
-
Dunne, Maurice
Vice President of Operations
425 867 1348
425 883 2896
-
Mueller, Jane
Vice President of Marketing
425 867 1348
425 883 2896
-
Murphy, Brenda 
Vice President of People
425 867 1348
425 883 2896

Pacey, John A.
Chief Executive Officer of Verathon Medical (Canada) ULC
425 867 1348
425 883 2896
drpacey@saturnbiomedical.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
